162 related articles for article (PubMed ID: 37485727)
21. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial.
Ballard C; Margallo-Lana M; Juszczak E; Douglas S; Swann A; Thomas A; O'Brien J; Everratt A; Sadler S; Maddison C; Lee L; Bannister C; Elvish R; Jacoby R
BMJ; 2005 Apr; 330(7496):874. PubMed ID: 15722369
[TBL] [Abstract][Full Text] [Related]
22. Rivastigmine for Alzheimer's disease.
Birks JS; Chong LY; Grimley Evans J
Cochrane Database Syst Rev; 2015 Sep; 9(9):CD001191. PubMed ID: 26393402
[TBL] [Abstract][Full Text] [Related]
23. Alzheimer's drug proves ineffective for delirium.
Harv Ment Health Lett; 2011 Mar; 27(9):7. PubMed ID: 21476248
[No Abstract] [Full Text] [Related]
24. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease.
Burns A; Spiegel R; Quarg P
Int J Geriatr Psychiatry; 2004 Mar; 19(3):243-9. PubMed ID: 15027039
[TBL] [Abstract][Full Text] [Related]
25. Impact of Rivastigmine on Cognitive Dysfunction and Falling in Parkinson's Disease Patients.
Li Z; Yu Z; Zhang J; Wang J; Sun C; Wang P; Zhang J
Eur Neurol; 2015; 74(1-2):86-91. PubMed ID: 26288230
[TBL] [Abstract][Full Text] [Related]
26. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.
Wolfson C; Oremus M; Shukla V; Momoli F; Demers L; Perrault A; Moride Y
Clin Ther; 2002 Jun; 24(6):862-86; discussion 837. PubMed ID: 12117079
[TBL] [Abstract][Full Text] [Related]
27. Rivastigmine for dementia associated with Parkinson's disease.
Emre M; Aarsland D; Albanese A; Byrne EJ; Deuschl G; De Deyn PP; Durif F; Kulisevsky J; van Laar T; Lees A; Poewe W; Robillard A; Rosa MM; Wolters E; Quarg P; Tekin S; Lane R
N Engl J Med; 2004 Dec; 351(24):2509-18. PubMed ID: 15590953
[TBL] [Abstract][Full Text] [Related]
28. Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.
Parsons C; Lim WY; Loy C; McGuinness B; Passmore P; Ward SA; Hughes C
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD009081. PubMed ID: 35608903
[TBL] [Abstract][Full Text] [Related]
29. Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study.
Mamikonyan E; Xie SX; Melvin E; Weintraub D
Mov Disord; 2015 Jun; 30(7):912-8. PubMed ID: 25914281
[TBL] [Abstract][Full Text] [Related]
30. Cholinesterase inhibition as a possible therapy for delirium in vascular dementia: a controlled, open 24-month study of 246 patients.
Moretti R; Torre P; Antonello RM; Cattaruzza T; Cazzato G
Am J Alzheimers Dis Other Demen; 2004; 19(6):333-9. PubMed ID: 15633941
[TBL] [Abstract][Full Text] [Related]
31. Rosuvastatin versus placebo for delirium in intensive care and subsequent cognitive impairment in patients with sepsis-associated acute respiratory distress syndrome: an ancillary study to a randomised controlled trial.
Needham DM; Colantuoni E; Dinglas VD; Hough CL; Wozniak AW; Jackson JC; Morris PE; Mendez-Tellez PA; Ely EW; Hopkins RO
Lancet Respir Med; 2016 Mar; 4(3):203-12. PubMed ID: 26832963
[TBL] [Abstract][Full Text] [Related]
32. Rivastigmine treatment of Othello syndrome and post-ECT delirium in a patient with Parkinson's disease.
Scicutella A
J Neuropsychiatry Clin Neurosci; 2015; 27(1):e90. PubMed ID: 25716514
[No Abstract] [Full Text] [Related]
33. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years.
Small GW; Kaufer D; Mendiondo MS; Quarg P; Spiegel R
Int J Clin Pract; 2005 Apr; 59(4):473-7. PubMed ID: 15853867
[TBL] [Abstract][Full Text] [Related]
34. Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology.
Touchon J; Bergman H; Bullock R; Rapatz G; Nagel J; Lane R
Curr Med Res Opin; 2006 Jan; 22(1):49-59. PubMed ID: 16393430
[TBL] [Abstract][Full Text] [Related]
35. Rivastigmine tartrate with a focus on dementia associated with Parkinson's disease.
Wesnes K
Drugs Today (Barc); 2007 Jun; 43(6):349-59. PubMed ID: 17612707
[TBL] [Abstract][Full Text] [Related]
36. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
Takeda A; Loveman E; Clegg A; Kirby J; Picot J; Payne E; Green C
Int J Geriatr Psychiatry; 2006 Jan; 21(1):17-28. PubMed ID: 16323253
[TBL] [Abstract][Full Text] [Related]
37. Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial.
Mowla A; Mosavinasab M; Haghshenas H; Borhani Haghighi A
J Clin Psychopharmacol; 2007 Oct; 27(5):484-7. PubMed ID: 17873681
[TBL] [Abstract][Full Text] [Related]
38. Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation.
Sharma T; Reed C; Aasen I; Kumari V
Schizophr Res; 2006 Jul; 85(1-3):73-83. PubMed ID: 16797163
[TBL] [Abstract][Full Text] [Related]
39. Do local meteorological conditions influence skin irritation caused by transdermal rivastigmine? A retroprospective, pilot study.
Segers K; Cytryn E; Surquin M
J Clin Psychopharmacol; 2012 Jun; 32(3):412-5. PubMed ID: 22544007
[TBL] [Abstract][Full Text] [Related]
40. A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease.
Narasimhalu K; Effendy S; Sim CH; Lee JM; Chen I; Hia SB; Xue HL; Corrales MP; Chang HM; Wong MC; Chen CP; Tan EK
Acta Neurol Scand; 2010 Apr; 121(4):217-24. PubMed ID: 19951274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
